tbuckley/cabot-search huggingface dataset:
The Impact of Systemic Factors on Clinical Response to Ranibizumab for Diabetic Macular Edema
Authors: Rishi P. Singh, Karishma Habbu, Justis P. Ehlers, M. Cecilia Lansang, Lauren Hill, Ivaylo Stoilov
Journal: Ophthalmology (2016)

To evaluate the effect of systemic factors on best-corrected visual acuity (BCVA) achieved with ranibizumab (Lucentis; Genentech, Inc, South San Francisco, CA) for treatment of diabetic macular edema (DME) in the RIDE and RISE phase 3 studies.Exploratory, post hoc analysis of 2 randomized, double-masked, sham-injection controlled studies.Adults with DME, BCVA of 20/40 to 20/320 Snellen equivalent, and central foveal thickness of 275 μm or more.Analysis of RIDE (clinicaltrials.gov identifier, NCT00473382) and RISE (clinicaltrials.gov identifier, NCT00473330) pooled ranibizumab data through month 24. Change in BCVA was assessed for association with the following covariates: age, body mass index (BMI), blood pressure, serum glucose, glycosylated hemoglobin (HbA1c), blood urea nitrogen, serum creatinine, estimated glomerular filtration rate, and blood chemistry variables. Change in BCVA at month 24 was assessed according to the following categories of diabetes medication use history: insulin only (n = 193), insulin plus other medications (n = 221), or other noninsulin medications (n = 331).Change in BCVA from baseline assessed by randomized treatment group in pooled 0.3- and 0.5-mg monthly ranibizumab groups.In patients with DME, vision improvement with ranibizumab was not influenced by systemic factors such as diabetes medication history, serum glucose, HbA1c, renal function, BMI, and blood pressure. Patients taking insulin with or without other medications at baseline had longer diabetes disease duration (mean, 17.4 and 20.9 years, respectively) compared with those taking other noninsulin medications (mean, 11.9 years). At month 24, among ranibizumab-treated patients, the mean BCVA change from baseline (Early Treatment Diabetic Retinopathy Study letters ± standard deviation) was not different between patients taking only insulin (12.6±11.2 letters), insulin plus other medications (12.2±12.4 letters), or other noninsulin medications (14.0±13.7 letters). Mean BCVA change also was comparable among patients taking thiazolidinediones (12.9±9.7 letters) and those not taking thiazolidinediones (13.2±13.3 letters).There were no associations between systemic factors (baseline values or change from baseline) and mean change of BCVA at month 24. These results suggest that visual response to ranibizumab therapy in DME was not influenced by nonocular factors related to systemic management of diabetes in the RIDE and RISE studies.
JAK2V617F Complete Molecular Remission in Long-Term Follow-up of Patients with Polycythemia Vera and Essential Thrombocythemia Treated with Ruxolitinib
Authors: Lisa Pieri, Alessandro Pancrazzi, Annalisa Pacilli, Claudia Rabuzzi, Giada Rotunno, Paola Guglielmelli, Rajmonda Fjerza, Chiara Paoli, Tiziana Fanelli, Alberto Bosi, Srdan Verstovsek, Alessandro Maria Vannucchi
Journal: Blood (2014)
Hemobilia in Hereditary Hemorrhagic Telangiectasia: An Unusual Complication of Endoscopic Retrograde Cholangiopancreatography
Authors: T.  Costa Macedo, R.  Maldonado, A.  Valente, R.  Palma, M.  Raimundo, M.  Liberato, I.  Távora, P.  Alexandrino, M.  Carneiro de Moura
Journal: Endoscopy (2003)

Hepatobiliary manifestations of hereditary hemorrhagic telangiectasia (HHT) are rare, but often involve cholestasis. We report here a case of HHT associated with cholestasis due to common bile duct stenosis. Attempted balloon dilation of the stenosis during endoscopic retrograde cholangiopancreatography (ERCP) resulted in hemobilia. Hemostasis was achieved by adjusting the nasobiliary drain. The aim of this report is to highlight the biliary manifestations of HHT and draw attention to an unusual complication of ERCP in this setting.
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
Authors: C N Harrison, A M Vannucchi, J-J Kiladjian, H K Al-Ali, H Gisslinger, L Knoops, F Cervantes, M M Jones, K Sun, M McQuitty, V Stalbovskaya, P Gopalakrishna, T Barbui
Journal: Leukemia (2016)

Abstract Ruxolitinib is a Janus kinase (JAK) (JAK1/JAK2) inhibitor that has demonstrated superiority over placebo and best available therapy (BAT) in the Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment (COMFORT) studies. COMFORT-II was a randomized (2:1), open-label phase 3 study in patients with myelofibrosis; patients randomized to BAT could crossover to ruxolitinib upon protocol-defined disease progression or after the primary end point, confounding long-term comparisons. At week 48, 28% (41/146) of patients randomized to ruxolitinib achieved ⩾35% decrease in spleen volume (primary end point) compared with no patients on BAT ( P &lt;0.001). Among the 78 patients (53.4%) in the ruxolitinib arm who achieved ⩾35% reductions in spleen volume at any time, the probability of maintaining response was 0.48 (95% confidence interval (CI), 0.35–0.60) at 5 years (median, 3.2 years). Median overall survival was not reached in the ruxolitinib arm and was 4.1 years in the BAT arm. There was a 33% reduction in risk of death with ruxolitinib compared with BAT by intent-to-treat analysis (hazard ratio (HR)=0.67; 95% CI, 0.44–1.02; P =0.06); the crossover-corrected HR was 0.44 (95% CI, 0.18–1.04; P =0.06). There was no unexpected increased incidence of adverse events with longer exposure. This final analysis showed that spleen volume reductions with ruxolitinib were maintained with continued therapy and may be associated with survival benefits.
The treatment of anorexia nervosa
Authors: A R Lucas, J W Duncan, V Piens
Journal: American Journal of Psychiatry (1976)

The authors report on their treatment of 32 young patients with severe anorexia nervosa who had lost an average of 37% of their original body weight. The therapeutic approach, conceived to meet both the physiological and the psychological needs of the patients, was carried out in a psychiatric unit for adolescents in a general hospital and involved separation of the patient from his or her family, treatment of the malnutrition, individually planned psychotherapy, and concurrent work with the family. The importance of accepting the patient's uniqueness, maintaining long-term contact, and encouraging the patient's striving toward constructive growth and autonomy is emphasized.
Impact of late-life depression on the social network
Authors: D G Blazer
Journal: American Journal of Psychiatry (1983)

The author tested the hypothesis that a major depressive disorder contributes to a decline in social support by studying data from 331 subjects 65 years of age and older who had been selected at random from a larger community group and screened for a major depressive disorder and the availability of social supports. Impaired social support was associated with the presence of a major depressive disorder. Thirty months later, however, the surviving subjects whose social supports had improved were 2.62 times more likely to have been depressed earlier than those whose social supports did not improve. Major depressive disorder was a significant predictor of improvement in social supports at follow-up.
Descriptive epidemiology of exanthems in the Rotterdam region January 1997 to June 1998
Authors: O Ronveaux, A Bosman, R Reintjes, M A E Conyn-Van Spaendonck
Journal: Eurosurveillance (1998)

The European Advisory Group on Immunisation has recommended that measles should be eliminated from Europe by the year 2007, a target accepted by National Immunisation Programme Managers for the World Health Organization (WHO) European Region countries. I
Bone metastases in patients with small cell lung carcinoma: Rate of development, modality of treatment, and their impact on survival.
Authors: Konstantinos N. Syrigos, Dimitrios Vassos, Ioannis Gkiozos, Paraskevi Boura, Serafeim Kaltsas, Elias Kotteas, Andriani Charpidou
Journal: Journal of Clinical Oncology (2015)

e18559 Background: Previous data as regards the exact impact of BMs and bone-targeted therapies on the overall prognosis of patients with SCLC are extremely limited. The aim of the present study was to shed more light on this issue, and further investigate the prognostic significance of early versus late development of bone metastases (BMs) among patients with SCLC. Methods: We performed a retrospective analysis of medical records of 363 patients with histologically or cytologically confirmed small cell lung carcinoma (SCLC), diagnosed and treated in our institution between January 2003 and December 2012. Clinicopathological features and survival data were correlated with the presence of BMs, their time point of development (early versus late onset) and their treatment modality (radiotherapy, bisphosphonates or both), in the entire study population and in the subgroups of patients with limited or extensive-stage disease (LD or ED-SCLC, respectively) at diagnosis. Results: Overall, 35.8% of our patients were diagnosed with BMs, either at diagnosis (early onset BMs, 26.7%) or at a subsequent time point (late onset BMs, 9.1%). Patients with early-onset BMs had a reduced overall survival (OS)as compared to those with late-onset BMs or those without BMs(p = 0.020). No statistically significant associations were observed between OS and the presence of BMs in the ED and LD subgroups of patients (p = 0.926 and p = 0.144, respectively). Treatment modality of BMs had no impact on OS either (p > 0.05). Multiple Cox regression analysis showed that increased age, poor performance status, presence of BMs and early onset BMs were independently associated with reduced OS. Conclusions: Our results suggest that the presence of early-onset BMs may represent an independent prognostic factor in patients with SCLC. In contrast, the type of modality employed for treatment of BMs had no statistically significant impact on survival in our study population.
Case 33-1987
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, William F. McNeely, Betty U. McNeely, Paul C. Shellito, Carolyn C. Compton
Journal: New England Journal of Medicine (1987)

Presentation of CaseA 46-year-old man was admitted to the hospital because of pain in the right lower abdominal quadrant.He was well until 9 or 10 days earlier, when fever and intermittent severe periumbilical pain developed, lasted for a day or two, and then became localized in the right lower abdominal quadrant. He came to the Emergency Ward of this hospital, where moderate anemia was found. An x-ray film of the chest was normal, and an x-ray film of the abdomen showed no abnormality. Oxycodone–acetaminophen was prescribed, without relief. During the week before entry the pain was mild and . . .
Selecting patients with cisplatin-resistant germ cell tumors for high-dose chemotherapy.
Authors: R J Motzer
Journal: Journal of Clinical Oncology (1996)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1996.14.10.2625 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8874319 Selecting patients with cisplatin-resistant germ cell tumors for high-dose chemotherapy. R J MotzerxR J MotzerSearch for articles by this author https://doi.org/10.1200/JCO.1996.14.10.2625 PDF "Selecting patients with cisplatin-resistant germ cell tumors for high-dose chemotherapy.." Journal of Clinical Oncology, 14(10), pp. 2625–2626© 1996 by American Society of Clinical Oncology
Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo-controlled study
Authors: C L Shriqui, J Bradwejn, L Annable, B D Jones
Journal: American Journal of Psychiatry (1992)

The authors compared vitamin E with placebo in a double-blind randomized crossover study of 27 patients with tardive dyskinesia. Each treatment period lasted for 6 weeks. Vitamin E showed no differences from placebo in the treatment of tardive dyskinesia.
Inhibitory Effect of Fumaric Acid on Hepatocarcinogenesis by Thioacetamide in Rats
Authors: K Kuroda, K Terao, M Akao
Journal: JNCI Journal of the National Cancer Institute (1987)

An inhibitory effect of fumaric acid (FA) on hepatocarcinogenesis was examined in rats fed thioacetamide (TAA). A group of male DONRYU rats were fed TAA at a level of 0.035% in the diet for 40 weeks and then fed a basal diet for 40 weeks. Hepatic carcinomas developed in 9 of 41 animals of this group fed TAA alone. The effect of FA on the carcinogenesis was examined in 2 groups fed both TAA and FA; one group of rats were fed FA at 1% in a basal diet after ingestion of TAA, and another group of rats were fed TAA plus a supplement of 1% FA in the diet. The inhibitory effect of FA on TAA carcinogenesis was so marked that no hepatic carcinomas were found in both groups fed FA in combination with TAA.
HEMORRHAGE COMPLICATING TRACHEOTOMY
Authors: E A HILDRETH
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Ex Vivo Culture of CD34+/Lin−/DR− Cells in Stroma-Derived Soluble Factors, Interleukin-3, and Macrophage Inflammatory Protein-1α Maintains Not Only Myeloid But Also Lymphoid Progenitors in a Novel Switch Culture Assay
Authors: Jeffrey S. Miller, Valarie McCullar, Catherine M. Verfaillie
Journal: Blood (1998)
The temporal relationship between depressive and psychotic symptoms in recent-onset schizophrenia
Authors: M F Green, K H Nuechterlein, J Ventura, J Mintz
Journal: American Journal of Psychiatry (1990)

The authors examined the temporal relationship between onset of depressive and psychotic symptoms in 27 patients with recent-onset schizophrenia or schizo-affective disorder. Ratings on the Brief Psychiatric Rating Scale were collected every 2 weeks for at least 1 year to specify onset of relapse or exacerbation. Six time periods were defined in relation to onset of psychotic symptoms, and the number of depressive periods was determined for each time period. Onset of depressive periods was concurrent with onset of psychosis more often than expected but was not associated with any other time period. The authors found no distinctive postpsychotic pattern of onset for depression.
Demonstration of Rickettsia conorii-induced endothelial injury in vivo by measuring circulating endothelial cells, thrombomodulin, and von Willebrand factor in patients with Mediterranean spotted fever [see comments]
Authors: F George, P Brouqui, MC Boffa, M Mutin, M Drancourt, C Brisson, D Raoult, J Sampol
Journal: Blood (1993)
THE TREATMENT OF PUERPERAL ECLAMPSIA
Authors: L DAFFNER
Journal: BMJ (1905)

T~E t.re~tment of puerperal eclampsi~ is one of the burning questŸ in obstetrics ~t the present time, a.nd I suppose tha.t during the 1)ast few yea.rs more ha, s been said ~nd wriiten a.bout ir t-ha.nanv other connected with the management of childbirth.But it is •lot my l)resent intent.ion to enter upon ah exhaus~ix'e eritieism of all the methods of treating this disease which a.re a.t present in vogue, but rather to make a few remarks asa contribution to the diseussion of Dr.I 91 5Iaouire's paper.In the first place, then, what do we know as to the nature of the eondition which we are so often called upoa to t.reat?Until quite recent, times I could hardly have deseribed ir as a disease but rat.her as a complex of symptoms.But sinee the publieation of the investigations of Lubarsch and Sehmorl ir is generally recognised tha.t this eondition is eharaeterised by eertain de¡ pathologieal and anatomical ehanges, consisting chiefly in degenerations and neeroses of the tissue eells, aecompanied by hamorrhages and t hrombosis, espeeially in the smallest veins.These ehanges whieh are always to be., found in t.he most important organs of the body~the brain, the heart, the liver, and the kidneys~are the, essentŸ features of this disease and not the symptoms, By SIR W.
Very high dose loxapine in refractory schizophrenic patients
Authors: C R Lehmann, L Ereshefsky, S R Saklad, T E Mings
Journal: American Journal of Psychiatry (1981)

The authors report on three chronic, treatment-refractory schizophrenic patients who dramatically improved when placed on very high doses of loxapine (300-500 mg/day). Numbness transiently appeared in two patients at very high doses of loxapine; it may be a frequently occurring but unreported side effect. The relative lack of serious side effects to very high dose loxapine suggests that this may be a useful intervention in carefully selected refractory patients. The authors recommend that controlled studies be done to elucidate the benefit to risk ratio.
Corrigendum to “Management of the critically ill patients with cirrhosis: A multidisciplinary perspective”
Authors: Mitra K. Nadim, Francois Durand, John A. Kellum, Josh Levitsky, Jacqueline G. O’Leary, Constantine J. Karvellas, Jasmohan S. Bajaj, Andrew Davenport, Rajiv Jalan, Paolo Angeli, Stephen H. Caldwell, Javier Fernández, Claire Francoz, Guadalupe Garcia-Tsao, Pere Ginès, Michael G. Ison, David J. Kramer, Ravindra L. Mehta, Richard Moreau, David Mulligan, Jody C. Olson, Elizabeth A. Pomfret, Marco Senzolo, Randolph H. Steadman, Ram M. Subramanian, Jean-Louis Vincent, Yuri S. Genyk
Journal: Journal of Hepatology (2016)
Design, synthesis of 1,4-cyclohexyldiamine substituted diaminopyrimidines as selective inhibitors of CDK1, CDK2 and CDK4 and their in vitro and in vivo evaluation
Authors: Qingjie Ding, Nan Jiang, Xin-Jie Chu, Allen Lovey, Wanda Depinto, Binh Vu, Dave Bartkovitz, John Mullin, Gerald Kaplan, John Moliterni, Kathryn Packman, Melissa Smith, Sung-Sau So, Bradford Graves, Christine Lukacs, Xuefeng Yin, Yingsi Chen
Journal: Cancer Research (2005)

4414   Cyclin dependent kinases (CDKs) play an important role in mammalian cell cycle progression. The malfunction and/or irregular expression of these CDKs have been identified as the cause of many uncontrolled proliferative diseases such as cancer. Inhibitors of specific CDKs, which regulate the transition between particular phases of the cell cycle, provide an opportunity for the discovery of new anti-cancer drugs. We have identified a series of 1,4-cyclohexyldiamine substituted diaminopyrimidines as selective CDK inhibitors with in vitro IC 50   50
Determination of Clinical Outcome in Mitral Regurgitation With Cardiovascular Magnetic Resonance Quantification
Authors: Saul G. Myerson, Joanna d’Arcy, Jonathan P. Christiansen, Laura E. Dobson, Raad Mohiaddin, Jane M. Francis, Bernard Prendergast, John P. Greenwood, Theodoros D. Karamitsos, Stefan Neubauer
Journal: Circulation (2016)

Surgery for severe mitral regurgitation is indicated if symptoms or left ventricular dilation or dysfunction occur. However, prognosis is already reduced by this stage, and earlier surgery on asymptomatic patients has been advocated if valve repair is likely, but identifying suitable patients for early surgery is difficult. Quantifying the regurgitation may help, but evidence for its link with outcome is limited. Cardiovascular magnetic resonance (CMR) can accurately quantify mitral regurgitation, and we examined whether this was associated with the future need for surgery.One hundred nine asymptomatic patients with echocardiographic moderate or severe mitral regurgitation had baseline CMR scans and were followed up for up to 8 years (mean, 2.5±1.9 years). CMR quantification accurately identified patients who progressed to symptoms or other indications for surgery: 91% of subjects with regurgitant volume ≤55 mL survived to 5 years without surgery compared with only 21% with regurgitant volume >55 mL (P<0.0001). A similar separation was observed for regurgitant fraction ≤40% and >40%. CMR-derived end-diastolic volume index showed a weaker association with outcome (proportions surviving without surgery at 5 years, 90% for left ventricular end-diastolic volume index <100 mL/m(2) versus 48% for ≥100 mL/m(2)) and added little to the discriminatory power of regurgitant fraction/volume alone.CMR quantification of mitral regurgitation was associated with the development of symptoms or other indications for surgery and showed better discriminatory ability than the reference-standard CMR-derived ventricular volumes. CMR may be able to identify appropriate patients for early surgery, with the potential to change clinical practice, although the clinical benefits of early surgery require confirmation in a clinical trial.
Epidemiology of Diabetes—Status of a Pandemic and Issues Around Metabolic Surgery
Authors: Paul Z. Zimmet, K. George M.M. Alberti
Journal: Diabetes Care (2016)

The number of people with diabetes worldwide has more than doubled during the past 20 years. One of the most worrying features of this rapid increase is the emergence of type 2 diabetes in children, adolescents, and young adults. Although the role of traditional risk factors for type 2 diabetes, such as genetic, lifestyle, and behavioral risk factors, has been given attention, recent research has focused on identifying the contributions of epigenetic mechanisms and the effect of the intrauterine environment. Epidemiological data predict an inexorable and unsustainable increase in global health expenditure attributable to diabetes, so disease prevention should be given high priority. An integrated approach is needed to prevent type 2 diabetes and must recognize its heterogeneity. Future research needs to be directed at improved understanding of the potential role of determinants, such as the maternal environment and other early life factors, as well as changing trends in global demography, to help shape disease prevention programs. Equally important is a better understanding of the role of metabolic surgery in helping to address the management both of persons with type 2 diabetes and of those persons in the community who are at higher risk for type 2 diabetes, particularly in emerging nations where the diabetes epidemic is in full flight.